Larazotide: Gut Permeability Protocol

Category: Protocols Type: Protocol Read Time: 14 minutes Author: Peptides.NYC Editorial Last Updated: 2026-05-19 URL: https://peptides.nyc/learn/larazotide-protocol

Educational content only. Not medical advice. Consult a licensed healthcare provider before starting any protocol, especially with celiac or autoimmune conditions.

Overview

Larazotide acetate (also known as AT-1001 and INN-202) is a synthetic 8-amino-acid peptide designed to act as an antagonist of the zonulin pathway in the small intestine. Unlike injectable peptides, Larazotide is administered orally and exerts its effects locally at the intestinal epithelium — it is not meaningfully absorbed systemically, which is part of its safety profile.

It was originally developed as an adjunctive therapy for celiac disease, intended to be taken alongside a gluten-free diet to help limit the tight junction disruption that occurs during inadvertent gluten exposure. Research has since broadened into other conditions involving impaired intestinal barrier function — colloquially known as "leaky gut."

Key Properties

• 8 amino acid synthetic peptide
• Oral administration (capsule, taken before meals)
• Acts locally in the small intestine
• Minimal systemic absorption
• Zonulin receptor antagonist
• Tight junction restoration mechanism
• Studied extensively in celiac (Phase 2/3 trials)

Mechanism of Action

The intestinal epithelium is sealed by tight junctions — protein complexes (occludin, claudins, ZO-1) that decide what passes between cells. When functioning normally, they form a selective barrier between gut contents and the bloodstream.

Zonulin — the human precursor of which is haptoglobin-2 — is an endogenous regulator of these junctions. When zonulin binds its receptor (involving EGFR and PAR2 signaling), tight junctions loosen, increasing paracellular permeability.

In susceptible individuals, two main triggers upregulate zonulin:

1. Gluten exposure (particularly gliadin fragments in genetically susceptible people)
2. Dysbiosis (overgrowth of certain gram-negative bacteria, LPS load)

Excess zonulin → opened tight junctions → larger molecules cross the barrier → immune activation and inflammation. This pathway has been characterized extensively in the research of Fasano, Leffler, and colleagues.

Larazotide blocks zonulin's effect at the receptor level, helping keep tight junctions closed during exposure events. The result is a more stable barrier rather than a "healing" effect in the regenerative sense — it's a brake on the opening signal.

Conditions Researched

The celiac dataset is by far the most robust. Other applications remain investigational and should be approached with appropriate caution.

Dosing Protocols

Clinical trial dosing has used the milligram range, taken multiple times daily before meals. The following table summarizes commonly referenced protocols.

Dose-finding note: Several Phase 2 trials found the 0.5 mg dose performed as well as or better than higher doses in celiac, suggesting a U-shaped dose response. More is not necessarily better.

Critical: Timing With Meals

This is the single most important practical detail of Larazotide use.

Larazotide must be taken BEFORE eating — typically 15 to 30 minutes prior. Taken after a meal, it is largely ineffective for its intended mechanism.

The reason is mechanistic: Larazotide works by pre-blocking the zonulin response that gluten and other triggers would otherwise initiate. Once tight junctions have already begun to open, the peptide cannot meaningfully reverse the event in real time. It is a preventive brake, not a rescue.

Practical implications:

• Pre-dose all meals, not just suspect ones
• Include snacks if they contain potential triggers
• Set phone reminders 15 minutes before scheduled meals
• If you forget, do not "double up" after — wait for the next meal
• Keep capsules portable for restaurant settings

Expected Outcomes

Larazotide produces gradual, not acute, results. Patients expecting BPC-157-like rapid relief will be disappointed — this peptide is a barrier stabilizer, not a regenerative agent.

Week 1–2

• Subtle reduction in post-meal bloating or discomfort
• May feel nothing dramatic
• Adaptation to dosing schedule

Week 4–6 (Celiac)

• Reduced symptom burden during inadvertent gluten exposure events
• Less severe "glutening" reactions reported in trials
• Improved day-to-day GI stability

Week 8–12

• Permeability biomarker improvements (lactulose/mannitol ratio, serum zonulin, LPS) in research settings
• Reduced systemic inflammation markers in some studies
• More resilient response to dietary indiscretions

Outcomes vary considerably. Patients with significant dysbiosis or untreated SIBO often see less benefit until those root issues are addressed.

Side Effects & Safety

Across Phase 2 and Phase 3 trials, Larazotide has demonstrated a favorable safety profile, with adverse event rates similar to placebo in many studies.

Reported (Generally Mild)

• Headache
• Transient GI symptoms (paradoxical — bloating, loose stools early on)
• Urinary tract symptom reports in some trials
• Fatigue (uncommon)
• Nausea (uncommon)

Reassuring Features

• Minimal systemic absorption
• No major organ toxicity signals in long-duration studies
• No significant drug interactions identified in trials
• Acts locally rather than via systemic hormonal pathways

Caution / Discuss With Provider

• Pregnancy and breastfeeding (insufficient data)
• Pediatric use outside of trials
• Concurrent immunosuppressive therapy
• Active malabsorption syndromes (absorption of co-administered drugs may shift)

Combining With Other Gut Peptides

Larazotide addresses one specific node — zonulin-mediated permeability. A comprehensive gut protocol often layers complementary agents that operate through different mechanisms.

Example Comprehensive Gut Protocol

• Larazotide: 0.5 mg, 3x/day, 15 min before meals
• BPC-157: 250–500 mcg/day (oral or SubQ)
• KPV: 200–400 mcg/day
• L-glutamine: 5 g, 2x/day on empty stomach
• Zinc carnosine: 75 mg, 2x/day with meals
• Targeted probiotic based on stool testing
• Duration: 8–12 weeks, then reassess

Always introduce one agent at a time when possible to identify what is working.

Larazotide vs Diet Alone

Larazotide is not a substitute for dietary management. In celiac disease, a strict gluten-free diet remains the foundation of care.

The intent of Larazotide is to provide additional protection against inadvertent exposure (cross-contamination at restaurants, hidden gluten in processed foods, social situations) and to dampen ongoing low-grade inflammation in patients whose symptoms persist despite dietary adherence.

It does not license eating gluten freely. Phase 3 data did not support use of Larazotide as a means of consuming gluten without consequence. The peptide reduces the magnitude of barrier disruption — it does not abolish it.

For non-celiac leaky gut, the same principle applies: eliminating dietary drivers (alcohol, NSAIDs when avoidable, identified food triggers) does more than any peptide can.

Stacking & Lifestyle

The intestinal barrier is regulated by far more than gluten. A complete approach addresses upstream drivers.

Diet

• Whole-food, low-ultra-processed pattern
• Adequate fiber for microbial diversity
• Polyphenol-rich foods (berries, olive oil, green tea)
• Limit alcohol (a known barrier disruptor)
• Identify personal triggers via elimination

Microbiome

• Test for SIBO if symptoms suggest (breath testing)
• Address dysbiosis before expecting Larazotide to "fix" permeability
• Consider stool testing for inflammatory markers

Stress and HPA Axis

• Zonulin release is influenced by HPA axis activity
• Chronic stress → elevated cortisol → barrier disruption
• Sleep, breath work, and stress regulation are not optional

Movement and Recovery

• Moderate exercise supports motility and microbiome diversity
• Avoid heavy NSAID use, which independently disrupts the barrier

Cycling

Unlike growth-hormone-axis peptides, Larazotide does not appear to require strict cycling for receptor protection.

• Active disease / persistent symptoms: Continuous use during the symptomatic period is reasonable
• Stable on strict diet: Many users taper to PRN dosing before higher-risk meals (travel, restaurants, social events)
• Long-term wellness use: 8–12 week structured protocols followed by reassessment are common
• No clear evidence of tolerance development at currently studied doses

Periodically reassessing whether the peptide is still adding value — versus diet, lifestyle, and microbiome work alone — is sensible.

Frequently Asked Questions

Q: Can I eat gluten freely if I take Larazotide? A: No. The clinical trials did not support this use case. Larazotide is an adjunct for celiac patients already maintaining a gluten-free diet, not a license to consume gluten.

Q: Is Larazotide FDA-approved? A: Not at the time of writing. Phase 3 trials in celiac have been completed and the program has been under review at various stages. Access has typically been through compounding pharmacies or research settings — not standard retail pharmacies.

Q: Is Larazotide better than L-glutamine for leaky gut? A: They work differently. L-glutamine provides fuel for enterocytes and supports general mucosal repair. Larazotide specifically blocks zonulin-driven tight junction opening. Many comprehensive protocols use both rather than choosing between them.

Q: Can Larazotide help with long COVID? A: There is emerging research on zonulin elevation in subsets of long COVID patients, and Larazotide has been studied in this context. Evidence is early-stage and not definitive. Discuss with a knowledgeable provider.

Q: Can I stack Larazotide with BPC-157? A: They are commonly combined. BPC-157 supports tissue healing while Larazotide prevents barrier opening. The mechanisms are complementary, not redundant.

Q: Where can I source Larazotide? A: Because it is not yet FDA-approved, access is typically through compounding pharmacies under a licensed provider's prescription, or through clinical trials. Always verify third-party COA testing and source legitimacy.

Q: How quickly will I notice results? A: Larazotide is a gradual agent. Most users feel subtle changes by week 2–4 and more meaningful changes by week 8–12. It is not a "feel it in an hour" peptide.

Q: Do I need to refrigerate Larazotide? A: Oral capsule formulations are generally shelf-stable at room temperature, but follow the specific guidance from your compounding pharmacy or supplier.

Related Content

• BPC-157 Complete Guide
• KPV Anti-Inflammatory Protocol
• Gut Healing Peptide Stack
• SIBO Testing Guide
• Compounding Pharmacy Guide

Disclaimer: This content is for educational purposes only and is not medical advice. Larazotide acetate is a research compound that has completed Phase 3 trials but is not currently FDA-approved for general use. Information is presented as a reference for clinical trial protocols and should not be construed as a treatment recommendation. Consult a licensed healthcare provider before starting any peptide protocol, particularly if you have celiac disease, an autoimmune condition, or other chronic gastrointestinal illness.

Source: https://peptides.nyc/learn/larazotide-protocol